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Abstract
Primary open-angle glaucoma is a progressive ocular neuropathy that if left untreated 
may lead to blindness. The main risk factor for developing glaucoma is increased intra-
ocular pressure. Intraocular pressure is regulated by the balance of aqueous humour 
synthesis and secretion into the eye and outflow from the eye; therefore, most therapies 
for glaucoma seek lowering intraocular pressure to avoid disease progression. There are 
several types of drugs in the market for the treatment of glaucoma, but there are still 
unmet needs to be overcome; therefore, significant effort has been put in the last few 
years to develop new medicines with innovative mechanisms of action as well as devices 
to improve quality of life in glaucoma patients. The present review offers a thorough 
revision of the latest advances in the glaucoma therapy field, focusing on innovative 
approaches, new targets and new mechanisms of action.
Keywords: glaucoma, innovation, therapy, oligonucleotides, devices, stem cells, gene 
therapy
1. Introduction
Primary open-angle glaucoma (POAG) is a multi-factorial optic neuropathy characterized 
by retinal ganglion cell degeneration and progressive visual field loss [1]. The underlying 
molecular changes leading to ocular tissue damage in glaucoma are largely unknown, but 
it has been shown that reduction in intraocular pressure (IOP) correlates with a decrease in 
disease progression. As such, treatment in glaucoma is mainly oriented towards reducing IOP 
to reach a target reduction of approximately 25–30% from the patient’s baseline [2]. Pressure 
in the eye is maintained by balancing the amount of fluid contained within the anterior and 
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posterior chambers; thus, reduction in IOP is achieved either by reducing the amount of aque-
ous humour (AH) secreted into the eye or by increasing its outflow [1]. AH is produced by 
the epithelial cells of the ciliary processes through a complex mechanism that involves ultra-
filtration, active transport and diffusion; AH is thereafter secreted into the posterior chamber. 
AH circulates from the posterior chamber around the lens and through the pupil into the 
anterior chamber and exits the eye trough one of two pathways: the conventional pathway 
or the uveoscleral route. AH exiting the anterior chamber through the conventional route 
crosses the trabecular meshwork (TM) to reach the Schlemm’s canal (SC) located at the lim-
bus. Contraction of the ciliary muscle causes the TM to expand and SC to open resulting in 
increased outflow through this route. The main source of outflow resistance through this 
route is the extracellular matrix of the TM and the inner wall endothelium of the SC. Through 
the unconventional or uveoscleral route, AH flows from the iris angle through the anterior 
face of ciliary muscle into the connective tissue located between the muscle bundles to finally 
reach the suprachoroidal space. The fluid is thereafter drained through the sclera or the peri-
vascular spaces into the episcleral tissue where it enters the venous circulation. In contrast to 
the conventional route, the main source of AH outflow resistance is the ciliary body [3].
The eye is a contained organ that is partially isolated from the rest of the body; this isolation 
provides a certain immune privilege and limits the amount of compound needed to perform 
proof-of concept studies. In addition, the eye has a sophisticated structure with many different 
cell types and specialized barriers making it an ideal organ for studying delivery of larger com-
pounds. As such, the eye has often been used to study new mechanisms of action and to obtain 
initial data for new compounds in development. Therefore, it is not surprising that most inno-
vative new classes of drugs have, at some point, been tested in the eye, among these new classes 
of drugs are aptamers, antisense oligonucleotides (ASO), short interfering RNAs (siRNA), anti-
bodies, stem cells, gene therapy and different types of delivery approaches and devices.
Here, we will review innovative programs developing drugs for the treatment of glaucoma 
focusing on the latest advances oriented towards lowering IOP, paying particular attention to 
the mechanisms used by these drugs and devices.
2. Pharmacological innovation
Progressive and irreversible loss of vision is the most feared complication for glaucoma. 
While current treatments focus on lowering IOP, up to date no therapies have been approved 
to address the critical issue of visual field deterioration. For this reason, high unmet needs 
remain for the development of innovative approaches to treat such aspect of the disease. 
Fortunately, beyond classic eye drop medicines, various exciting therapies are emerging in 
the field. Overall, these techniques aim to provide either a novel alternative to reduce IOP or a 
protection and regeneration of retinal ganglion cells (RGCs) to ultimately reverse vision loss. 
In this section, we will describe novel techniques for the treatment of glaucoma. Interestingly, 
these complex strategies have been combined in order to achieve broader efficacy.
Traditionally, drug discovery has been based on screening large libraries of compounds to 
select products with specific activities. However, in the last decades, advances in the molecular 
Glaucoma - Intraocular Pressure and Aqueous Dynamics88
biology field have allowed the search for active candidates to become more rational. As a 
result, new pharmaceuticals with innovative mechanisms of action, target specific design and 
improved pharmaceutical properties have emerged. Some of the advantages of these new com-
pounds include increased specificity, reduced toxicity and the ability to address targets that 
cannot be engaged by traditional small molecules. Among these new pharmaceuticals are bio-
logicals, stem cells, gene therapy and therapies based on oligonucleotides.
Developing innovative compounds for the treatment of glaucoma entails thus targeting the 
function of cells and tissues related to IOP control; these tissues include the ciliary muscle, the 
TM, the SC, collector channels and aqueous veins. The latest discoveries in molecular biology 
allow the identification of key molecules that control AH dynamics in these tissues, and these 
molecules can be used as starting point for new therapeutic strategies and discovery of new 
targets. In order to fully take advantage of these approaches, the characteristics of these specific 
tissues have to be taken into account when designing the therapeutic strategy. The following 
characteristics are particularly interesting when developing innovative glaucoma therapies:
1.  The TM is composed of phagocytotically active cells; this facilitates the entrance of com-
pounds that exert their action inside the cell. Phagocytosis may be enhanced by some 
surgical procedures.
2.  Many of the cells of the TM are non-proliferative, terminally differentiated cells; this pro-
longs the action of certain therapies that can exert their action inside cells such as genetic 
therapies, antibodies and oligonucleotide-based therapies.
3.  The TM and the SC are structures with the ability to present antigens and induce toler-
ance; this may work in favour of some therapies that usually induce an immune response.
4.  Tissues responsible for IOP control are located in the anterior chamber and are more 
accessible than tissues of the back of the eye; therefore, invasive procedures are not usu-
ally required.
2.1. New drug targets
As mentioned above, current approaches to develop new drugs for the treatment of glaucoma 
are aimed towards decreasing IOP to avoid further damage to the glaucomatous eye. Five 
drug-types are currently approved to treat glaucoma: alpha agonists, beta-blockers, carbonic 
anhydrase inhibitors, prostaglandin analogues and cholinergic drugs. Given the information 
available from the field of genetics, it is surprising that no new targets have reached the clinic 
since prostaglandin analogues, but this may change in the near future. Here, we review the 
information and mechanistic data existing for three new targets against which several com-
pounds are currently under clinical development.
2.1.1. Rho-associated protein kinase (ROCK) inhibitors
2.1.1.1. Description and biological function
The Rho family consists of three guanosine triphosphate (GTP)-binding proteins named 
RhoA, RhoB and RhoC, which belong to the Ras-superfamily of GTPases [4]. Rho proteins 
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bound to guanosine diphosphate (GDP) remain inactive in the cytoplasm of the cell; upon 
binding of GTP, these proteins become active and translocate to the cellular membrane where 
they exert their function [5]. The Rho activation and inactivation cycle is regulated by GTP-ase 
activating proteins (GAP) and guanine nucleotide-exchange factors (GEFs) that catalyse GTP 
and GDP exchange [6]. Rho proteins are ubiquitously expressed and participate in the regula-
tion of cytoskeletal dynamics, thus playing a central role in cell morphology, adhesion and 
migration, as well as in numerous signalling pathways [7]. Increased levels of RhoA expres-
sion have been detected in optic nerve head of glaucomatous eyes [8].
One of the most comprehensively studied effectors of Rho proteins is the Rho-associated 
coiled-coil containing protein kinases (ROCK), which are serine-threonine kinases composed 
of a catalytic domain, a coiled-coin Rho-binding site and an auto-inhibitory domain [9]. In 
humans, ROCKs exist as two isoforms, ROCK1 and ROCK2, expressed in a wide variety of 
tissues including the TM and the ciliary muscle cells [10]. Multiple studies indicate that ROCK 
regulate the contractile properties of the TM, synthesis of extra-cellular matrix (ECM) and 
outflow of AH through the TM; factors known to be involved in AH dynamics [11]. In addi-
tion, ROCK1 and ROCK2 knock-out mice exhibit lower values of IOP when compared to 
those of their wild-type littermates [12].
2.1.1.2. Mechanism of action
Upon activation, ROCK phosphorylates a large number of substrates inducing their acti-
vation or inhibition; many of these substrates, such as the myosin light chain (MLC), the 
myosin phosphatase (MLP) and actin-binding LIM kinase (LIMK), actively participate in 
cytoskeletal dynamics and cell motility of the TM, SC and ciliary muscle [13, 14]. The con-
traction/relaxation status of these structures influences the resistance to AH outflow and 
as a result modulate IOP homeostasis. In consequence, the results of multiple studies have 
proposed a role of ROCK inhibitors in enhancing AH drainage through the TM by alter-
ing the cytoskeleton [15]. NF-κβ is another downstream effector of the ROCK pathway; its 
activation controls the translation of pro-inflammatory mediators such as interleukins or 
TNF-α.
The anti-fibrotic activity of ROCK inhibitors seems also to be relevant to the therapeutic role 
of these agents in glaucoma. Post-operative scaring is one of the main causes of filtration sur-
gery failure; scaring tissue formed at the TM leads to poor IOP control and allows silent dis-
ease progression. The differentiation of fibroblasts to myofibroblasts during wound healing 
and scar formation is mediated by TGF-β that facilitates the contractile response of fibroblasts. 
ROCK inhibitors such as Y-27632 and AMA0526 have demonstrated to improve surgical out-
come in animal models of glaucoma filtration surgery [16, 17]. Additionally, ROCK inhibitors 
such as Y-39983 and fasudil have been found to improve blood flow to the optic nerve head, 
seemingly due to their action on MLC that regulates the contraction of smooth muscle cells 
in the blood vessels irrigating this area [18, 19]. Finally, it has been shown that ROCK may 
also have an effect on central nervous system (CNS) targets involved in neuronal survival 
and axonal regeneration thus giving ROCK inhibitors an added-on value to their role on AH 
dynamics [20].
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2.1.1.3. Drugs in development
Y-27632 was the first identified ROCK specific inhibitor, and SNJ-1656 (also known as Y-39983/
RKI983; Senju and Novartis Pharmaceuticals) was the first ROCK inhibitor to demonstrate an 
IOP-lowering effect in human subjects [21]. Despite its effect in humans, the clinical develop-
ment of this compound was halted in Phase II due to insufficient efficacy and a poor toler-
ability profile [22]. ROCK inhibitors currently undergoing clinical trials in glaucoma include 
ripasudil (KowaCompany, Ltd; Japan), netarsudil (Aerie Pharmaceuticals, Inc; USA), PG324 
(Aerie Pharmaceuticals, Inc; USA) and AMA0076 (Amakem; Belgium).
Ripasudil hydrochloride hydrate, formerly known as K-115 (Glanatec® ophthalmic solution 
0.4%), was approved in Japan in September 2014 for the treatment of glaucoma and ocular 
hypertension when other therapeutic drugs are not effective or cannot be administered, at the 
dosage of one drop per eye, twice daily (b.i.d) [23, 24]. Compiled data from Phase II and III 
clinical trials indicated that this drug achieved a 15% IOP reduction (3.5 mmHg), being con-
junctival hyperaemia the most frequently reported adverse event with incidence rates rang-
ing from 55 to 74% [25, 26]. Non-clinical studies proved that ripasudil inhibited both ROCK1 
and ROCK2 (IC50 0.051 and 0.019 μmol/L, respectively) and mechanistic studies performed 
in rabbits demonstrated that its ocular hypotensive effect is due to increased drainage of AH 
through the TM and SC [27]. Ripasudil induces cytoskeletal changes secondary to ROCK inhi-
bition that lead to the retraction and rounding of the TM cells decreasing the compaction of 
the TM allowing aqueous outflow. Additionally, in vitro studies demonstrated that ripasudil 
reduced outflow resistance and increased SC endothelial cell permeability [28].
Netarsudil (RhopressaTM ophthalmic solution, 0.02%), formerly known as AR-13324, is a 
ROCK and a norepinephrine transporter (NET) inhibitor currently in Phase III clinical trials 
[29]. In a Phase II study, this product achieved a 22% reduction in mean diurnal IOP after 28 
treatment days when administered in eye drops once daily (q.d). However, non-inferiority 
versus latanoprost was not met [30]. IOP reduction is thought to be achieved by three differ-
ent mechanisms of action: increasing AH outflow through the TM, reducing the pressure in 
the epliscleral vein and reducing AH synthesis. Real-time effect of netarsudil on AH dynam-
ics was evaluated in vivo both in albino and pigmented mice using a custom-made optical 
coherence tomography system [31]. This technique confirmed that the IOP-lowering effect of 
netarsudil is related to its action both in proximal and distal steps of the outflow pathway. It 
was noted that the observed cytoskeletal changes induced by netarsudil caused the expansion 
of the conventional outflow tissues such as the TM and the SC avoiding its collapse at ele-
vated IOP. As a NET inhibitor, netarsudil is thought to decrease AH secretion since elevated 
norepinephrine levels activate α2 adrenergic receptors responsible for AH production at the 
ciliary processes [32]. Finally, netarsudil is also thought to have vasodilator properties as it 
reduces episcleral venous pressure in rabbits facilitating AH drainage to the bloodstream [32]. 
Similarly to ripasudil, ocular hyperaemia was the most frequently reported AE during clini-
cal development with incidence rates of 57% which improved during the course of the study 
decreasing to 24% after 28 treatment days.
RoclatanTM, formerly known as PG323, is a fixed dose combination (FDC) of netarsudil 0.02% 
and latanoprost 0.005%, which combines the previously described mechanisms of action with 
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the capacity of the prostaglandins of increasing AH outflow through the uveoscleral pathway 
[33, 34]. This fixed combination currently in Phase III clinical trials achieved clinically and sta-
tistically superiority in terms of ocular hypotensive efficacy when compared to its individual 
active components at the same concentrations. However, incidence rates of ocular hyperae-
mia were superior in the FDC than those observed in the latanoprost group (40 vs. 60%).
AMA0076 is a locally acting ROCK inhibitor currently in Phase II clinical trials specifically 
designed to reduce IOP while minimizing side effects such as hyperemia. In vivo studies 
conducted in an acute hypertensive rabbit model showed that AMA0076 prevented IOP ele-
vation more efficiently than latanoprost and bimatoprost. In vitro studies conducted in rab-
bit ocular tissues demonstrated that AMA0076 was able to induce reversible changes in cell 
shape and decreased the number of actin filaments and focal adhesions that may facilitate 
AH outflow [35].
2.1.2. Adenosine receptor ligands
2.1.2.1. Description and biological function
Adenosine is an endogenous nucleoside modulator of both intracellular and extracellu-
lar origin. Adenosine half-life is very limited (~1.5 seconds) as it is rapidly metabolized to 
inosine and hipoxantine; this is why extracellular levels of adenosine, which usually range 
from 20 to 200 nM, are considered a good indicator of cellular homeostasis. Adenosine levels 
increase, even up to the micromolar range, in response to cellular stress conditions such as 
tissue hypoxia or ischemia. In fact, adenosine levels in AH are significantly elevated in ocular 
hypertensive individuals when compared to normotensive individuals [36, 37].
Adenosine receptors (ARs) belong to the family of G protein-coupled receptors (GPCR) [37]. 
Four subtypes of AR have been identified (A1, A2A, A2B and A3), and all of them are involved 
in regulation of cAMP production through different pathways: A1 and A3 down-regulate 
cAMP levels inhibiting adenylyl cyclase, whereas A2A and A2B receptors activate adenylyl 
cyclase, increasing cAMP production. ARs are expressed in numerous ocular tissues such 
as ciliary body, TM, SC and retina. Activation/inactivation of ARs impacts AH formation, 
outflow and consequently IOP homeostasis. Additionally, ARs are also involved in retinal 
function, impacting blood flow and neuronal survival [36].
2.1.2.2. Mechanism of action
Activation of A3 receptors results in activation of Cl−channels in the non-pigmented ciliary 
epithelial (NPE) cells of the ciliary epithelium where AH is produced [38]. Studies conducted 
in A3AR knockout mice and in mice treated with A3AR antagonists showed that absence or 
inhibition of this receptor significantly decreases IOP when compared to native or untreated 
animals [39]. On the contrary, mice treated with A3AR agonists show enhanced chloride 
release resulting in increased AH production and rise in IOP. AR can also affect AH outflow; 
there are two pathways by which AR agonists increase conventional outflow through the TM 
and SC: cell volume modification mediated by ion transport and ECM remodelling [36]. A1, 
A2A and A3 AR agonists have shown to increase Ca2+ in the cells of the SC and to diminish 
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TM cell volume [40]. Outflow resistance in the TM is dependent on the composition of the 
ECM; activation of A1 ARs triggers signalling cascades that lead to the expression of high lev-
els of metalloproteases such a MMP-2 and MMP-9, enzymes participating in ECM remodel-
ling enhancing AH outflow and decreasing IOP. On the contrary, A2A and A2B AR activation 
increase ECM deposition and therefore difficult AH outflow increasing IOP [41].
In view of the previously exposed mechanisms, it can be concluded that AR ligands play a key 
role in IOP control. In general terms, adenosine binding to A1AR in the TM reduces outflow 
resistance. However, A2A AR stimulation may result in IOP increase or decrease depending 
on the alterations to the resistance in the SC. Finally, activation of A3 AR mediates activation 
of Cl−channels in the NPE cells inducing AH production, while A3 AR antagonists prevent 
adenosine-induced activation of Cl− channels decreasing IOP.
2.1.2.3. Drugs in development
Numerous AR ligands (both agonists and antagonists) are being developed with the purpose 
of exploiting their potential for modulation of IOP. The adenosine analogues that are cur-
rently in glaucoma clinical trials include trabodenoson (Inotek Pharmaceuticals, US), OPA-
6566 (Acucela, US and Otsuka Pharmaceutical, Japan), ATL-313 (Santen Pharmaceutical) and 
CF-101 (Can-Fite Bio Pharma, US).
Trabodenoson, formerly known as INO-8875/PJ-875, is a highly selective A1 AR agonist 
administered in eye drops currently in Phase III clinical trials. The IOP-lowering effect of four 
different doses of trabodenoson ranging from 50 to 500 μg was evaluated when administered 
b.i.d during 28 consecutive days in a Phase II clinical trial [42]. Administration of trabodeno-
son resulted in a dose-related IOP reduction; the highest dose tested achieved a statistically 
significant IOP reduction in 25% (6.5 mmHg) when compared to placebo. All the doses tested 
showed a good tolerability profile. The proposed mechanism of action for trabodenoson 
involves activation of the A1 adenosine receptor that promotes phosphorylation of the extra-
cellular signal-regulated kinases ERK1 and ERK2, resulting in increased secretion of MMP-2 
and changes in the ECM that decrease TM resistance to the AH outflow.
OPA-6566 and ATL-313 are two A2A agonists currently in Phase I clinical trials; at this point 
of development, little information on their clinical development is available. Both drugs are 
anticipated to increase AH outflow via the conventional pathway of the TM and SC rather 
than the uveoscleral pathway.
CF-101 is an A3 AR agonist orally administered presently in Phase II clinical trials. Recently, 
CF-1001 failed to meet its primary endpoint as no statistically significant differences in IOP 
were found between the CF101 group and the placebo group after 16 treatment weeks.
2.1.3. Nitric oxide donors
2.1.3.1. Description and biological function
Nitric oxide (NO) is a gaseous endogenous signalling molecule synthesized by nitric oxide 
synthases (NOS) that catalyse the oxidation of the amino acid L-arginine to form NO and 
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L-citrulline. There are three NOS isoforms: the neuronal NOS (nNOS or NOS-1), the endo-
thelial NOS (eNOS or NOS-3) and the inducible NOS (iNOS or NOS-2). NOS-1 and NOS-3 
are activated by the calcium/calmodulin complex in response to an increase in calcium and 
produce NO in the pico- or nanomolar scale. On the contrary, NOS-2 activation is calcium 
independent and produces NO in a micro- to millimolar scale [43].
NOS-3 is expressed in TM, SC, ciliary body and uveal vascular endothelium. NOS-1 is located 
in nerve fibres in the cornea and lens epithelium and iNOS is detected after directed stimula-
tion in the TM and in the ciliary body and vessels. This expression pattern of NOS enzymes 
in the anterior segment of the eye suggests that NO plays a key role in the regulation of AH 
dynamics. In fact, levels of NO and NOS expression are diminished in glaucomatous human 
eyes. In addition, NOS-3 knock-out mice exhibit elevated IOP levels due to a reduction in 
the conventional outflow, whereas the opposite effect is observed in NOS-3 over expressing 
transgenic mice [43, 44].
2.1.3.2. Mechanism of action
NO stimulates soluble guanylatecyclase (sGC) leading to the elevation of intracellular cyclic 
guanosine monophosphate (cGMP levels), a secondary messenger that interacts with protein 
kinases and phosphodiesterases. Multiple studies indicate that the NO-cGMP pathway regu-
lates IOP levels increasing AH outflow through the conventional route and by reducing AH 
secretion [43].
Cytoskeletal changes at the TM seem to be the underlying mechanism mediating the increase 
in AH outflow induced by NO. NO induces vascular smooth muscle cells (VSMC) relaxation 
by stimulation of cGMP synthesis that subsequently activates protein kinase G (PKG). This 
results in inhibition of the Rho-kinase cascade and leads to inhibition of the MLC-2 phosphor-
ylation. Analogously to VSMCs, TM cells also exhibit contractile properties and modulation 
of these properties by NO is thought to mediate changes that result in a reduction in outflow 
resistance. Additionally, it has been demonstrated that inhibition of multi-drug resistance-
associated protein-4 also induces TM cellular relaxation mediated by cGMP-PKG pathway 
[45]. NO could also mediate its IOP-lowering effects by targeting cells of the SC. In fact, Rho-
kinase inhibition mediated by NO-cGMP regulates actin dynamics and cell contractility in 
cultured SC cells [46].
2.1.3.3. Drugs in development
Latanoprostene bunod (LBN; BOL-303259-X; Bausch & Lomb) is a novel nitric oxide-donat-
ing prostaglandin F2a analogue currently in Phase III clinical trials [47]. In the eye, LBN is 
metabolized to two moieties. The first, latanoprost acid, is an F2alpha prostaglandin analogue, 
while the second, butanediol mononitrate, releases nitric oxide, which activates the soluble 
cGMP signalling pathway. LBN achieves IOP control simultaneously enhancing AH outflow 
through the conventional and the uveoscleral routes. Doses ranging from 0.006 to 0.040% of 
LBN solution were administered once a day to patients with OAG or OHT for 28 consecutive 
days. LBN at 0.024 and 0.040% achieved statistically significant reductions in mean IOP when 
compared to latanoprost. During the Phase III clinical trial LBN 0.024% (QD) was not only 
Glaucoma - Intraocular Pressure and Aqueous Dynamics94
non-inferior to timolol maleate 0.5% dosed twice daily (b.i.d) after 3 months of treatment but 
also provided significantly greater IOP reduction. LBN exhibited a similar safety profile than 
prostaglandins being conjunctival hyperaemia the most frequently reported AE.
2.2. New mechanisms of action
New drug targets are certainly playing an important part in modernising the way glaucoma 
will be treated in the future. But innovation in glaucoma is not only focused in the discovery 
of new drug targets, but it is also taking advantage of new and exciting mechanisms of action 
that seek to solve unmet needs that current treatments cannot solve. In the following sec-
tion, we will give an overview of drugs using innovative mechanisms of action, focusing on 
those that have in the past few years entered in clinical development for glaucoma. It should 
be noted that although antibodies fall into this category of drugs using new mechanisms of 
action, they have not been included in this section since, up to the authors’ knowledge, there 
are no clinical programmes currently developing antibodies for the treatment of glaucoma. A 
section on neuroprotective drugs has been included at the end of this section to highlight the 
importance these drugs are acquiring in the glaucoma pipeline.
2.2.1. Oligonucleotide-based compounds
Oligonucleotides have in the past decades turned out to be an interesting therapeutic approach, 
particularly due to their ability to address intracellular targets. Oligonucleotides can be 
designed to target specific genes or RNAs with the aim of altering gene expression or even 
exert a direct interaction by binding to molecules. The main classes of oligonucleotides that are 
currently being developed as therapeutic tools are aptamers, ASOs, siRNAs and microRNAs 
(miRNAs) [48].
2.2.1.1. Aptamers
Aptamers are RNA or DNA oligonucleotides that form a 3D structure designed to interact 
with large or small molecules. Aptamers typically bind to proteins but can be designed to 
act upon other types of molecules [49]. Aptamers, contrary to antibodies, are chemically 
synthetized products that do not require biological steps in their production processes; this 
results in products that are very well controlled without significant variability among batches. 
Aptamers have not been widely tested in the context of glaucoma. Pegaptanib, a first-in-class 
FDA-approved aptamer for the treatment of age-associated macular degeneration (AMD), 
has been briefly studied for the treatment of neovascular glaucoma [50]. This compound 
binds to a subtype vascular endothelial growth factor (VEGF), VEGF
165
,
 
hampering its ability 
to bind to its cell surface receptor thus impairing neovascularization [51]. In addition, ARC81, 
an anti-transforming growth factor-β (TGF-β) aptamer, has been studied for the reduction in 
corneal scaring, a common complication of glaucoma filtration surgery [52].
2.2.1.2. Antisense oligonucleotides (ASOs)
ASOs are single-strand RNA or DNA oligonucleotides, of approximately 15–25 bp, that medi-
ate mRNA degradation by an RNaseH-mediated mechanism [53]. These compounds have 
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been widely used to study cell function and lately applied to therapeutics. There are two FDA 
approved ASOs; vitravene, an intravireally administered ASO for the treatment of cytomega-
lovirus retinitis in AIDS patients and mipomersen, an intravenously administered ASO for 
the treatment of familiar hypercholesterolemia [54, 55]. The main advantage of this class of 
compounds is that they modulate gene expression without altering the genetic code, and that 
their action upon their target gene can be rapidly modified. In addition, as other oligonucle-
otides, ASOs are chemically synthetized, with all the advantages this entails. On the other 
hand, ASOs are labile products that require chemical modifications to increase their stability; 
these modifications can potentially increase their toxicity [48, 56].
There are two ASOs under development for treatment of different types of glaucoma; 
Aganirsen (GS-101) and ISTH0036. Aganirsen is a 25-bp ASO targeting insulin receptor sub-
strate-1 (IRS-1) administered in eye drops; this compound is being developed for the treat-
ment of corneal neovascularization and has also been tested in neovascular glaucoma [57]. 
ISTH0036 is a fully modified phosphorothioate 14-bp oligodeoxynucleotide with a 3 + 3 LNA-
gapmer pattern targeting TGF-β2. TGF-β2 is an anti-proliferative and anti-inflammatory 
factor that is upregulated in the AH of POAG patients. Increases in TGF-β2 correlate with 
deposition of fibrillar extracellular matrix in the TM, one of the hallmarks of POAG [58]. 
These extracellular depositions in the TM hamper AH outflow and consequently result in IOP 
increase. ISTH0036 is currently being tested in a Phase I dose-finding clinical study in patients 
with advanced glaucoma undergoing filtration surgery due to uncontrollable elevated IOP. 
The compound is administered intravitreally (IVT) at the end of trabeculectomy; the out-
comes of the study are safety, tolerability and effect on IOP.
2.2.1.3. Short interfering RNAs (siRNAs)
siRNAs are double-stranded RNA molecules of approximately 19–25 bp that mediate gene 
silencing by blocking translation of specific mRNAs into their corresponding protein [59]. 
These molecules, although usually larger than ASOs, are in general more potent and stable 
than ASOs. Depending on the target tissue and the level of expression of the target gene, these 
compounds can be administered in eye drops avoiding invasive administration methods, if 
deeper regions need to be accessed IVT administration may be required [60]. In addition, once 
the siRNA has entered the RISC complex its action lasts for quite some time, this means that 
a single molecule would be able to mediate the degradation of several mRNAs thus amplify-
ing the effect of the compound. This prolonged action is particularly interesting in the case of 
glaucoma as it could avoid sudden increases in IOP due to skipped doses.
Bamosiran (SYL040012) is a 21-bp unmodified siRNA targeting adrenergic receptor β2 
(ADRB2) for the treatment of glaucoma. This compound is administered in eye drops and 
penetrates the eye to reduce synthesis of AH by blocking the ADRB2 at the ciliary body and 
possibly also at the TM [61, 62]. In contrast to traditional beta-blockers, bamosiran acts only 
locally in the eye; this is because the molecule is rapidly degraded when it reaches systemic 
circulation, thus reducing the likelihood of systemic side effects. This characteristic makes 
bamosiran a safe compound for the treatment of individuals with risk of heart disease or 
other alterations in which beta-blockers are contraindicated.
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QPI-1007 is a 19-bp siRNA targeting Caspase-2. This product, administered by IVT injection, 
is under development for the treatment of several optic neuropathies, including glaucoma 
[63]. Caspase-2 is specifically activated during ganglion cell death leading to irreversible loss 
of vision, thus reducing its expression could potentially protect retinal ganglion cells from 
apoptosis.
2.2.2. Gene therapy
Gene therapy is a technique that uses genetic material to modify the disease state, usually 
using a vector to transfer the genetic material. For ophthalmic affectations, distinct viral vec-
tors can be used for the delivery of such genetic material. Most-studied vectors include adeno-
virus (AdV), adeno-associated virus (AAV), herpes simplex virus (HSV) and lentivirus; all 
of them offering distinct pros and cons [64]. While large advancement has been achieved in 
different eye diseases, gene therapy for glaucoma has faced substantial limitation due to the 
lack of obvious genetic alterations. Indeed, causative and risk factor genes such as myocilin 
(MYOC), optineurin (OPTN), Cytochrome P450 1B1 (CYP1B1), caveolin (CAV1/CAV2) and 
TANK-binding kinase 1 (TBK1), among others, represent less than 10% of glaucoma cases 
worldwide [65]. Up to date, only one gene therapy trial for glaucoma has been listed (Trial 
ID: US-0589). This Phase I study proposes to evaluate the safety of SCH-412499 (rAd-p21) 
after a single injection into the sub-conjunctival space of the eye in glaucoma subjects prior 
to trabeculectomy. The treatment uses an AdV vector for the expression of p21 WAF-1/Cip1, 
a potent cyclin-dependent kinase inhibitor to reduce wound healing process and fibroprolif-
eration after filtering surgery [66]. No results have been disclosed yet; however, pre-clinical 
studies demonstrated a safe profile with strong anti-proliferative effect after filtration surgery 
in animal models [67, 68].
In collaboration with Mayo Clinic (Rochester, USA), Oxford BioMedica plc (Oxford, UK) is 
developing a novel gene therapy approach for the treatment of chronic glaucoma. Pre-clinical 
studies have been undertaken to determine the feasibility of the LentiVector® platform for the 
delivery and expression of cyclooxygenase (COX-2) and prostaglandin F2α (PGF-2α) genes to 
reduce IOP in glaucomatous patients. According to the company’s announcement, pre-clinical 
studies demonstrated a good tolerance for the LentiVector® when used at high doses, with the 
ability to transduce proper target cells following transcorneal injection into the anterior cham-
ber. Moreover, data showed a long-term gene expression for up to 5 months. Although pre-
clinical efficacy studies on IOP have been planned, no additional results have been published.
Besides these two emerging gene therapy treatments for glaucoma, most investigational 
developments are still in pre-clinical phases, showing relative effect on IOP. For example, the 
COX-2 and PGF-2α gene therapy models previously described demonstrated a prolonged 
decrease in IOP in large animal models [69]. Similarly, using lentiviral-based dual expression 
vector to deliver prostaglandin F synthase, significant reduction in IOP has been achieved 
[70]. However, the overall reduction in IOP produced by these vectors was not as extensive as 
that observed for topical PG eye drops. Likewise, different gene therapy strategies to modu-
late the RhoA or Rho-kinase pathways showed an efficient but moderate IOP-lowering effect 
[71, 72]. In an elegant way, gene therapy has also been adapted to steroid-induced glaucoma. 
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In these patients, topical instillation of glucocorticoids is known to produce ocular hyperten-
sion by producing a downregulation of the matrix metalloproteinase 1 (MMP1) gene in the 
TM. Because the patients are under an on and off treatment schedule with glucocorticoids, a 
new self-complementary AAV has been generated for the expression of MMP1 under the con-
trol of a glucocorticoid response element. This allows for the induction of MMP1 expression 
only after the administration of glucocorticoids, a strategy that presents great advantages. 
Using this novel system, a reduction in IOP was detected in large animal model and would be 
highly beneficial in clinic [73].
In addition to cell transduction and adequate gene expression modulation, the route of 
administration is a critical factor for effective gene therapy. Interestingly, optimum delivery 
and transduction of AdV have been found through the TM and the SC, structures from where 
the AH flows [74]. However, the complexity of the whole outflow tract, which includes vari-
ous cell-types harbouring different transduction properties, may impair the overall efficacy 
of gene therapy. Moreover, the possible systemic exposure with unwanted side effects is an 
important downside of direct release of viral vectors that can drain into the retinal venous cir-
culation. Although we are still a long way from the instauration of gene therapy in glaucoma 
treatment, the advancement achieved in the field is encouraging and sustains the feasibility 
of such technique in human.
2.2.3. Stem cell therapy
Once glaucoma has reached advanced stages with irreversible vision loss, the nearly unique 
alternative is to replace the retinal ganglion cells of the optic nerve to restore functional vision. 
Hence, future objectives aim at regenerating the optic nerve in blind eyes using stem cell 
therapy. While the majority of clinical trials using stem cells have been conducted in neuro-
retinal degenerative diseases, trials in glaucoma are only starting to emerge. This is because 
the replacement of RGCs is a most tricky task and will depend on (1) cell engraftment, differ-
entiation and migration to the ganglion cell layer, (2) the growth of axons into the optic disc 
and (3) the establishment of effective synapse connection [75]. To do so, cells can be implanted 
into different compartments of the eye, although most commonly tested sites are intravitreal 
or sub-retinal. The stem cells used can be of various sources and are often engineered in 
vitro through gene therapy [76]. Autologous transplantation of genetically modified cells that 
originate from the same patient has been favoured due to larger safety window, reducing 
host-defense mechanism and immune reaction such as those produced by AdV viral vectors. 
Because of the novelty of these methodologies, the primary goals of current registered clinical 
trials are towered first on safety outcomes (monitoring of adverse and serious adverse reac-
tion), and secondary outcomes on efficacy (visual acuity, eye fundus and visual field improve-
ment). In general, patients with advanced stages of glaucoma are recruited because of the lack 
of previous safety studies involving humans.
A novel Phase II trial aims to test the efficacy and safety of adipose-derived regenerative cells 
for the treatment of glaucomatous neurodegeration (NCT02144103). After liposuction, cells are 
harvested and isolated from fat tissues and injected into the same patient by subtenon admin-
istration. The rationale behind the use of adipose-derived mesenchymal stem cells is based on 
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their capacity to differentiate into retinal pigment epithelium cells. Another promising treat-
ment uses autologous bone marrow-derived stem cells (BMSC): after prior isolation and culture, 
these cells are injected intravitreally into the worst eye of the patient (NCT02330978). Safety 
parameters are the first objective of this Phase I trial, although an improvement in visual acu-
ity and visual field are expected in secondary outcomes. Mechanisms for such potential effects 
remain uncertain. Surprisingly, in animal models, BMSCs have been shown to survive after 
intravitreal injection, although without showing any apparent differentiation ability. There 
are actual evidences that BMSC cannot pass the vitreoretinal interface, suggesting that BMSCs 
may act in a paracrine manner, most likely by providing neuroprotection, rather than by dif-
ferentiating into RGCs [77]. A larger clinical trial is currently running to evaluate the efficacy of 
such BMSC therapy, comparing distinct injection sites for various ophthalmic diseases, includ-
ing glaucoma (NCT01920867). Routes of injection include retrobulbar, subtenon, intravenous, 
intravitreal and intraocular, which may provide valuable information on the ability of BMSCs 
to improve visual acuity depending on the delivery site. Overall, big hopes are expected from 
these trials and their success would definitively represent important breakthrough.
Aside from clinical trials, numerous pre-clinical studies are underway to explore the capacity 
of different stem cell populations to provide neuroprotection or regeneration of optic nerves. 
For example, a novel stem cell therapy has been explored to prevent the loss of TM function 
and cell number observed in glaucoma. The TM and SC operate to drain out the AH and play 
pivotal role in sensing IOP fluctuation. In conjunction with the modulation of the extra-cel-
lular matrix and enzymes activity, these two structures adapt to adjust the resistance to fluid 
flow. The aim of this new stem cell therapy, although still at pre-clinical stages, is to obtain 
new functional TM-like cells to restore functional outflow tract. Recently, in a mouse model 
of glaucoma, transplantation of induced pluripotent stem cells (iPSC) differentiated into TM 
cells was shown to reduce neuronal loss and IOP [78]. Surprisingly, the cell transplant led 
to increased proliferation of pre-existing TM cells. Obviously, further investigation will be 
needed to confirm the feasibility of these innovative therapies and to efficiently apply them 
to regular clinical practice.
2.2.4. Neuroprotective drugs
Transport of neurotrophic factors (NTFs) along RGCs axons is critical for cell survival, and unfor-
tunately, this process is found altered in glaucoma. Indeed, the mechanical compression of the 
optic nerve hinders retrograde travelling of NFTs, leading to induction of the apoptotic cascade. 
Neuroprotective therapy thus aims to prevent RGCs cell death and damage of the optic nerve. 
Neuroprotective drugs have been initially developed for the treatment of various neuropathic 
diseases and their success raised the possible application for the prevention of vision loss in 
glaucoma. Pre-clinical studies have clearly demonstrated the efficacy of neuroprotective therapy 
for glaucoma; however, it has not yet been translated into clinic. When looking retrospectively, 
the development of such therapies has been hampered by the failure of Memantine to meet its 
primary outcome in Phase II trials, and consequently the drop from clinical development. This 
drug belongs to a new class of Alzheimer’s disease medications that inhibits NMDA receptors 
to counteract the toxic effect of L-glutamate accumulation into the nervous system. It has been 
shown to strongly reduce RGCs loss in various animal species [79]. Unfortunately, Memantine 
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failed to demonstrate any protective properties in glaucoma patients [80]. Consequently, com-
panies became skeptical over undertaking such risky clinical trials. Up to date, the main dif-
ficulty relies on the fact that long-term efficacy for neuroprotection is extremely hard to prove. 
Nonetheless, the rationale behind this therapy remains valid and is still currently explored, 
mostly that a myriad of signalling pathways can be modulated to protect RGCs. The fact that 
many of these targets act through an IOP independent manner provides an appealing approach 
to treat patients with normal tension glaucoma. This chapter will explore some of these avenues, 
focusing on survival factors, apoptotic mechanisms and oxidative stress.
One of the best strategies to achieve neuroprotection focuses on the delivery of NTFs to RGCs 
using cell therapy. A Phase I clinical trial has been completed to evaluate the safety and effi-
cacy of the NT-501 CNTF Implant after intravitreal injection into one selected eye (Neurotech 
Pharmaceuticals, Inc; NCT01408472). The implant contains human cells (designated NTC-
201) that originate from a retinal pigment epithelial cell line genetically engineered to produce 
human ciliary neurotrophic factor (CNTF). A role for CNTF in neuroprotection of the retina 
has been established in a wide number of pre-clinical studies, which was shown to promote 
cell survival of RGCs in most animal models [81]. In human, such implant has been previously 
proved to release CNTF consistently over a 2-year period without producing systemic expo-
sure, hence avoiding the need for multiple injections [82]. Outcomes have not been reported 
yet but studies suggest favourable pharmacokinetic of the implant with possible treatment of 
chronic retinal degenerative diseases. Overall, MSCs and BMDS transplant represent a valu-
able tool for long-term delivery of various NTFs as well as anti-inflammatory cytokines that 
may prevent apoptosis of RGCs.
Activation of apoptosis is a key mechanism in RGCs cell death and increasing amount of 
anti-apoptotic agents are currently being investigated for the treatment of glaucoma. Since 
apoptosis often occurs in early stages of the disease, its detection is of prime importance to 
prevent irreversible damage lost. A new Phase I study is evaluating the ability of ANX776 
to identify RGC apoptosis as part of a new detection of apoptosing retinal cells (DARC) 
technique (NCT02394613). The primary purpose of the study is to develop a new diagnosis 
tool for glaucoma in healthy patients. As previously described, QPI-1007 is a promising can-
didate to achieve neuroprotection by reducing the expression of Caspase-2 (NCT01965106 
and NCT01064505). Interestingly, brimonidine, a selective alpha2-adrenergic agonist, has 
been shown to protect against optic nerve damage independently of its IOP-lowering effect, 
most likely by inducing the production of the anti-apoptotic proteins Bcl-2 and Bcl-XL [83]. 
Effectively, in a clinical trial, normal tension glaucoma patients treated with brimonidine dis-
played preserved field function as compared to those that were given timolol [84]. Curiously, 
other classic IOP reducing agents have been proved to yield neuroprotective effect because of 
a dual mechanism of action. A different example is the beta adrenergic blocker Betaxolol. This 
drug interacts with other channels such as the sodium and L-type calcium channels, an affin-
ity that was proposed to contribute to the protection of the visual field observed in treated 
patients [85]. Interestingly, a Phase III trial named ‘Stop Retinal Ganglion Cell Dysfunction 
Study’ is currently running to compare the protective effect of numerous hypotensive medi-
cations routinely used in clinic (NCT02390284). The trial recruits patients with normal vision 
and eyes are evaluated for changes in the pattern electroretinogram (PERG) and retinal nerve 
fibre layer (RNFL) thickness.
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Anti-oxidants also represent an attractive alternative to prevent long-term RGC damage. Due 
to high metabolic activity during visual transduction, retinal cells are particularly sensitive 
to oxidative stress, mainly in elderly. Increased levels of reactive oxygen species (ROS) and 
associated DNA damage have been reported in glaucoma patients [86]. Numerous pre-clin-
ical studies in glaucoma animal models have shown a neuroprotective benefit for a large 
variety of anti-oxidant such as Vitamin E, Coenzyme Q10, Ginkgo biloba extract and other 
Chinese medicines [79]. One clinical trial previously addressed the impact of oral versatile 
anti-oxidants on glaucoma progression, comparing Ginkgo biloba and α-tocopherol for 3 
Therapy Description Phase/stage Outcome Trial ID
ASO Intra-vitreal injection of 
ISTH0036 as an addition to 
filtration surgery
Phase I/recruiting Safety and tolerability NCT02406833
siRNA Bamosiran eye drops for 
POAG
Phase II/completed Safety, dose finding,  
IOP-lowering effect
NCT02250612
siRNA QPI-1007 injection in 
primary angle closure 
glaucoma
Phase II completed Safety and tolerability 
and pharmacokinetics
NCT01965106
Gene therapy Intraocular delivery of p21 
WAF-1/Cip1 gene before 
glaucoma surgery
PhaseI/unknown Safety and tolerability, 
fibroproliferation and  
wound healing
US-0589
Gene therapy LentiVector® platform for 
the delivery of COX-2 and 
PGF-2α to reduce IOP
Pre-clinical Safety, IOP-lowering 
effect
Stem cell therapy Subtenon injection 
of adipose-derived 
regenerative cells
Phase II/recruiting Safety, change in visual 
acuity, eye fundus,  
visual field
NCT02144103
Stem cell therapy Intra-vitrial injection of 
BMSCs
Phase I/recruiting Safety, change in visual 
acuity and visual field, 
optical coherence 
tomography, RGC 
function
NCT02330978
Stem cell therapy Retro-bulbar, subtenon, 
intra-venous, intra-vitreal 
and intraocular injection  
of BMSCs
Phase II/recruiting Change in visual acuity 
and visual field
NCT01920867
Stem cell therapy, 
neuroprotection
Delivery of NT-501 CNTF 
Implant
Phase I/completed Safety, vision, visual 
field, nerve fibre layer, 
optic nerve topography
NCT01408472
Neuroprotection RGCs protection by 
hypotensive eye drops
Phase III/recruiting Change in PERG, RNFL NCT02390284
Neuroprotection Single intra-venous 
injection of ANX776 as  
new detection of 
apoptosing retinal cells 
(DARC) technique
Phase I/active Safety and DARC count NCT02394613
Table 1. Current clinical trials for new mechanisms of action for glaucoma.
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months (NCT01544192), however no clear benefits have been reported, and other similar 
studies failed to find differences among treatments (Table 1) [87].
3. Innovation in medical devices and surgical procedures
There are two types of surgical procedures aimed at lowering IOP, trabeculoplasty and tra-
beculectomy. The former is aimed towards treating the TM with LASER to diminish AH 
resistance and increase drainage into collecting channels or into the outside of the eye. In 
the latter, a part of the TM is removed to reduce resistance to outflow. These approaches 
usually reduce IOP for a period of up to 5 years, but additional medical or surgical interven-
tions are commonly required after this period due to scaring or secondary complications. 
Improvements in surgery thus seek using artificial channels that enlarge drainage routes or 
shunts that bypass the TM draining the AH directly to the SC or to the suprachoroidal space 
[88]. In the last decade, minimally invasive glaucoma surgery (MIGS) has gained popularity 
due to its minimal tissue destruction, short surgery time and fast post-operative recovery. 
Here, we present an overview of glaucoma draining devices that are in development for 
these procedures.
3.1. Drainage devices to the SC or to the sub-conjunctival space
The SC is an endothelium-lined channel derived from the TM located at the joining point of 
the sclera and cornea. The TM is composed of three layers: the innermost uveal meshwork, 
the middle layer section composed of connective tissue called the corneoscleral meshwork 
and the third layer, also known as juxtacanalicular tissue. The juxtacanicular tissue is a non-
fenenstrated endothelial layer immersed in fibres and a rich extra-cellular matrix that lines 
the inner wall of the SC. In humans, 75% of the resistance to AH outflow is exerted by the TM, 
mainly by the juxtacanalicular portion and the deposition of glycosaminoglycans in the TM 
ECM [89]. As such, bypassing the TM draining the liquid to the SC has been widely used as 
an approach to alleviate elevated IOP. Several devices are currently under development with 
the aim of improving the outflow through the TM.
3.1.1. Devices in development
The Glaukos iStent (Glaukos Corporation, Laguna Hills, CA, USA) is a heparin-coated micro 
stent that bypasses the TM by creating a pathway from the anterior chamber to the SC [90]. 
Implantation of this device in patients undergoing cataract surgery resulted in a sustained 
decrease in IOP (IOP ≤ 21 mmHg) in 72% of patients 12 months after implantation compared 
to 50% in the control group. Twenty-four months after surgery 61% still had IOP levels below 
21 mmHg whereas in the control group 50% of patients maintained the targeted IOP. Other 
outcomes included in the study, such as decrease in IOP ≥ 20% and medications reduction, 
were also positive for the device-implanted patient group. Further studies have shown that 
sustained elevated IOP may affect the shape of the SC and therefore implanting one iStent may 
not be sufficient to achieve a sustained decrease in IOP. To solve this issue studies implanting 
several iStents have been performed showing promising data [91].
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The Hydrus microstent (Ivantis Inc., Irvine, CA, USA) is an intra-canalicular scaffold made of 
nitinol that is surgically implanted into the SC during cataract surgery. This device is manu-
factured to follow the curve of the SC and widens the opening of the canal avoiding its col-
lapse. The efficacy of this device has been studied in patients undergoing cataract surgery 
and the results of these studies show that reduction in washed out diurnal IOP ≥ 20% was 
higher in the implanted group compared to the cataract surgery alone group 24 months after 
surgery (80 vs. 46%). Implantation of the device was also able to reduce the use of hypotensive 
medications [92].
InnFocus Microsunt, previously known as the MIDI Arrow (InnFocus Inc., Miami, FL, USA), 
is made of poly(styrene-block-isobutylene-block-styrene) SIBS, a synthetic thermoplastic elas-
tomeric biomaterial that does not cause inflammation. The implant is used in conjunction 
with Mitomycin C to modulate would healing post-surgery. This device is placed in the ante-
rior chamber and drains into the scleral surface [93]. The device was implanted in 23 eyes that 
had failed maximum tolerated glaucoma medication. The patients were followed for a period 
of 3 years; 14 patients received the implant alone whereas the rest were implanted concomi-
tantly to cataract surgery. Years 1, 2 and 3 after the procedure 100, 91 and 95% of the patients 
fulfilled the success criteria of the study (IOP ≤ 14 mm Hg and IOP reduction ≥20%), and the 
mean number of glaucoma medications was reduced from 2.4 ± 0.9 to 0.3 ± 0.8, 0.4 ± 1.0 and 0.7 
± 1.1, respectively. Adverse events of the procedure included transient hypotony (13%) and 
transient choroidal effusion (8.7%); both adverse events resolved spontaneously [94].
The XEN45 Gel Stent (Allergan, Dublin, Ireland) is a soft flexible implant initially developed 
by AqueSys but later acquired by Allergan. The device is manufactured in collagen-derived 
gelatine cross-linked with glutaraldehyde and is injected through the anterior chamber into 
the sub-conjunctival space. The device swells upon hydration creating the channel. The XEN45 
is approved in Europe, Turkey, Canada and Switzerland for reduction in IOP in patients with 
POAG where previous medical treatments have failed and is in late stage development in the 
USA. In Europe, the device can be used in conjunction with cataract surgery or as a standalone 
procedure. The data obtained from clinical trials show a mean drop of 47% from preoperative 
IOP in the standalone procedure and a 40% decrease when combined with cataract surgery. 
The main adverse events of this procedure include intra-operative sub-conjunctival or anterior 
chamber bleeding (1.2%), cataract-related complications (0.8%), post-operative hyphema (2.6%), 
self-limiting choroidal effusion (1%) shallow anterior chamber (0.8%), viscoelastic injection into 
the anterior chamber (0.6%) and anterior chamber tap to release retained viscoelastic (0.4%).
3.2. Drainage devices to the suprachoroidal space
There are several devices designed to drain AH from the anterior chamber to the supracho-
roidal space, where the fluid is reabsorbed by the scleral channels of the choriocapillaries. 
These devices are based on the existence of a difference in hydrostatic pressure between the 
supra-choroidal space and the anterior chamber; this difference favours unidirectional flow 
from the anterior chamber to the suprachoroidal space reducing IOP. The materials used to 
manufacture these devices vary from gold to non-biodegradable polymers; materials that are 
inert, non-biodegradable and biocompatible to ensure proper function of the device.
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3.2.1. Devices in development
The CyPass (Transcend Medical, Menlo Park, CA, USA) is a fenestrated polyamide supracili-
ary device that connects the anterior chamber with the suprachoroidal space. The device is 
implanted during cataract surgery and its efficacy has been tested in a multi-centre, prospec-
tive study enrolling 136 subjects with two cohorts. Cohort 1 was composed of subjects with 
OAG requiring cataract surgery that had uncontrolled IOP (IOP; ≥21 mmHg, n = 51), whereas 
cohort 2 was composed of subjects with OAG requiring cataract surgery with controlled IOP 
(<21 mmHg, n = 85). Glaucoma medications were stopped post-surgery but could be restarted 
if needed. The results of the study indicate that there was a reduction of 37% in mean IOP 24 
months after surgery. There was a statistically significant decrease in the need for glaucoma 
medications in both cohorts [95]. Further development of this device includes a randomized 
controlled trial that is currently underway (Table 2).
The SOLX gold shunt (SOLX Inc., Waltham, MA, USA) communicates the anterior chamber 
with the suprachoroidal space via 19 channels formed between the two 24-karat medical-
grade gold plates that form the shunt. The device is approved in Europe but still investiga-
tional in the USA. Several clinical trials have been conducted for this device with different 
outcomes. Success for this device was defined as a target IOP between 5 and 22 mmHg and 
an IOP decrease ≤20%. Most clinical studies for this device have yielded a success rate around 
80%. In contrast, in a study performed by Hueber and co-workers enrolling 31 patients 
implanted with the device and followed up for a period of 4 years most patients (97%) failed 
Table 2. Devices in development for glaucoma.
Device Manufacturer Material Status Trial ID
Devices draining  
to the SC or to the 
sub-conjunctival 
space
iSTENT Glaukos 
Corporation
Non-ferromagnetic 
titanium
FDA approved in 
patients undergoing 
cataract surgery. 
Phase IV
NCT00326066
Hydrus  
microstent
Ivantis Nitinol (alloy of 
nickel and titanium)
Phase III NCT01539239
InnFocus 
Microshunt
InnFocus Poly(styrene-block-
isobutylene-block-
styrene) SIBS
Phase IV NCT02177123
XEN45 Allergan 
(AqueSys)
Collagen-derived 
gelatine
Phase IV NTC02006693
Devices draining to 
the suprachoroidal 
space
CyPass Transcend 
Medical
Non-biodegradable 
polyimide
Safety and Efficacy NCT01085357
SOLX gold shunt SOLX Gold Phase III NCT01282346
Aquashunt OPKO health Polypropylene Safety and Efficacy NCT00834223
STARflo iSTAR Medicals Silicone microporus 
material
Safety and Efficacy NCT02272569
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the established success criteria. This difference outcome may be due to a fibrotic reaction to 
the device in this particular trial [96].
The Aquashunt (OPKO Health Inc., Miami, FL, USA) is a device made of polypropylene 
curved to accommodate the eye’s shape. The results from a clinical study enrolling 15 patients 
with uncontrolled IOP indicate that eight of the patients achieved an IOP reduction of 31%, 
four of which needed concurrent medical therapy to reach satisfactory IOP after a period of 
12 months. Further clinical studies have not been initiated [96].
The STARflo glaucoma implant (iSTAR Medical SA, Wavre, Belgium) is made of a micropo-
rous silicon elastomer and implanted intrascleraly into the suprachoroidal space. Clinical 
data are available from a limited number of cases, and it shows a reduction in the pre-oper-
ative IOP of 37.0 mmHg to a post-operative IOP of 14.3 mmHg 12 months after implanta-
tion. The reduction in glaucoma medication intake went from 3.25 medications/day to 1.5 
intake/day.
4. Conclusions
Current medical therapy for glaucoma is insufficient to avoid the deleterious effects of this 
progressive ophthalmic neuropathy. In the last decade, significant efforts have been made 
in order to develop new products that use novel approaches to address the unmet needs of 
a disease that is still the second cause of blindness. This review gives an overview of these 
approaches, focusing on new targets that regulate AH balance in the eye or that are involved 
in fibrosis and scaring; processes that complicate the long-term success of glaucoma filtration 
surgery.
New mechanism of actions such as therapies based on oligonucleotides, gene therapy and 
stem cells is also reviewed. Products based on these mechanisms of action are already show-
ing promising results in the clinical setting and may represent new options for patients that 
have uncontrolled IOP and that do not respond to current therapy.
A brief overview of neuroprotective approaches is also given; products based on this approach 
represent an excellent complementary option for IOP reduction strategies.
Finally, improvements in medical devices used to increase AH outflow are also reviewed. 
New devices achieve significant reduction in IOP and many can be used as stand-alone pro-
cedures offering an option to patients and settings where glaucoma medications are not a 
medically viable option.
Innovation in glaucoma may eventually change current disease treatment paradigms in order 
to offer solutions to a wider number of patients for whom current treatment options cannot 
stall disease progression. Achieving a sustained IOP reduction that warrants optic nerve pro-
tection over time is the main goal to be achieved, and some of these products may contribute 
towards that goal. As it has been the case for current glaucoma therapy, significant advances in 
quality of life of glaucoma patients may come from combining different approaches together 
to treat glaucoma in a comprehensive way.
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